Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 7/20 | 0.77 |
| ▸ | CES1 | P23141 | 7/20 | 0.77 |
| ▸ | GAPDH | P04406 | 4/20 | 0.75 |
| ▸ | S100A4 | P26447 | 1/20 | 0.60 |
| ▸ | IDO1 | P14902 | 2/20 | 0.59 |
| ▸ | CDC25A | P30304 | 2/20 | 0.59 |
| ▸ | CDC25B | P30305 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | P4HB | P07237 | 1/20 | 0.50 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17594909 | 0.91 | GAPDH (0.89) | CES2CES1GAPDHS100A4IDO1 | |
| SCHEMBL29647693 | 0.87 | CES1 (0.77) | CES2CES1GAPDHIDO1CDC25A | |
| SCHEMBL9628251 | 0.87 | CES1 (0.77) | CES2CES1GAPDHIDO1CDC25A | |
| SCHEMBL4468407 | 0.86 | GAPDH (1.00) | CES2CES1GAPDHS100A4IDO1 | |
| SCHEMBL9713857 | 0.85 | CES2 (0.60) | CES2CES1GAPDHS100A4IDO1 | |
| SCHEMBL17594484 | 0.83 | GAPDH (0.75) | CES2CES1GAPDHS100A4IDO1 | |
| SCHEMBL28916510 | 0.83 | GAPDH (0.75) | CES2CES1GAPDHS100A4IDO1 | |
| SCHEMBL9628376 | 0.83 | CES1 (0.77) | CES2CES1GAPDHS100A4IDO1 | |
| SCHEMBL9654781 | 0.83 | GAPDH (0.69) | CES2CES1GAPDHS100A4IDO1 | |
| SCHEMBL19420524 | 0.83 | GAPDH (0.64) | CES2CES1GAPDHS100A4IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| EP-0410172-A2 | 2-Halogeno-3-phenoxy-1,4-naphthoquinone derivatives | BAYER AG (DE) | 1991-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | KLK3, ACP3, NR5A1 | CES2 2901/4885CES1 928/4885GAPDH 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.